Danazol for Treatment of Cytopenias in Patients With Cirrhosis

Summary

This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.

Timeline

Start

2024-08-01

Primary completion

2027-08-01

Completion

2027-08-01

Drugs

Indications